Delayed diagnosis of multiple sclerosis in a low prevalence country

References

• Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018;4:43.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343–369.
   PubMedGoogle Scholar
• Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the world; 2013.
   Google Scholar
• Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scandinav. 1975;52:137–157.
   PubMed Web of Science ®Google Scholar
• Chalmer TA, Baggesen LM, Nørgaard M, et al. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25:1262–e110.
   PubMed Web of Science ®Google Scholar
• Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23:1233–1240.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–1116.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83:78–86.
   PubMed Web of Science ®Google Scholar
• Kappos L, O’Connor P, Radue E-W, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582–1591.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Castelo-Branco A, Svedbom A, et al. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. J Neurol. 2018;265:701–707.
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Kollman C, O’Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:678–684.
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987–997.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Kuhle J, Puhan MA, et al. Factors associated with time from first-symptoms to diagnosis and treatment initiation of multiple sclerosis in Switzerland. Mult Scler J - Exp Transl Clin. 2018;4:2055217318814562. .
   Google Scholar
• Sánchez JL, Aguirre C, Arcos-Burgos OM, et al. Prevalencia de la esclerosis múltiple en Colombia. Rev Neurol. 2000;31:1101–1103.
   PubMed Web of Science ®Google Scholar
• Toro J, Sarmiento OL, Díaz Del Castillo A, et al. Prevalence of multiple sclerosis in Bogotá, Colombia. Neuroepidemiology. 2007;28:33–38.
   PubMed Web of Science ®Google Scholar
• Jiménez C, Zarco L, Castañeda C, et al. Estado actual de la esclerosis múltiple en Colombia. Acta Neurológica Colomb. 2015;31:385–390.
   Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, et al. Changes in the ascertainment of multiple sclerosis. Neurology. 2005;65:1066–1070.
   PubMed Web of Science ®Google Scholar
• Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–568.
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–231.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Lee DH, Peschke M, Utz KS, et al. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol. 2019;26:540–545.
   PubMed Web of Science ®Google Scholar
• Aires A, Barros A, Machado C, et al. Diagnostic delay of multiple sclerosis in a Portuguese population. Acta Med Port. 2019;32:289–294.
   PubMed Web of Science ®Google Scholar
• Kingwell E, Leung AL, Roger E, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci. 2010;292:57–62.
   PubMed Web of Science ®Google Scholar
• Guillemin F, Baumann C, Epstein J, et al. Older age at multiple sclerosis onset is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology. 2017;48:179–187.
   PubMed Web of Science ®Google Scholar
• Thormann A, Sørensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017;89:1668–1675.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72:117–124.
   PubMed Web of Science ®Google Scholar
• Barin L, Kamm CP, Salmen A, et al. How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. Mult Scler. 2020;26:489–500.
   PubMed Web of Science ®Google Scholar
• McKay KA, Tremlett H, Fisk JD, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90:e1316–23.
   PubMed Web of Science ®Google Scholar
• Fernández O, Fernández V, Arbizu T, et al. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study). J Neurol. 2010;257:1500–1507.
   PubMed Web of Science ®Google Scholar
• Patrucco L, Rojas JI, Miguez JS, et al. Application of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinean cohort of patients with clinically isolated syndromes. Mult Scler. 2013;19:1297–1301.
   PubMed Web of Science ®Google Scholar
• OECD. Health care use - Magnetic resonance imaging (MRI) exams - OECD Data. 2019. DOI:10.1787/1d89353f-en.
   Google Scholar
• OECD. Health equipment - Magnetic resonance imaging (MRI) units - OECD Data. 2019. DOI:10.1787/1a72e7d1-en.
   Google Scholar
• Ministerio de Salud y Protección Social. Atlas de Variaciones Geográficas en Salud de Colombia 2015- Estudio piloto - Resultados de uso de resonancias magnéticas; 2015.
   Google Scholar